Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

2024 年 12 月 6 日 - 8 日，欧洲肿瘤内科学会亚洲年会（ESMO Asia）将在新加坡盛大召开。本届会议将汇聚全球专家学者，集中展示和讨论肿瘤学领域的最新科学和临床进展，为肿瘤领域带来一场学术盛宴。此次会议中，「Dato-DXd ...

AI-Enabled Drug Discovery is on the verge of a new revolution, with the first data emerging from exciting research indicating ...

A technology has been developed that can analyze tumor mutations in lung cancer patients to confirm drug resistance to ...

China’s drug regulator approved Alpha Biopharma Ltd.’s EGFR tyrosine kinase inhibitor (TKI), Zorifer (zorifertinib hydrochloride tablets; AZD-3759), as a first-line treatment for EGFR-mutated ...

EGFR tyrosine kinase inhibitors (TKIs) are effective treatments for EGFR-mutant non-small cell lung cancer (NSCLC). However, ...

CURE® spoke with a lung cancer treatment expert about study findings showing survival benefits with the addition of ...

In September, amivantamab (Rybrevant; Johnson & Johnson) received its fourth treatment indication from the FDA to treat ...

The Lung Cancer Research Foundation (LCRF) and the International Association for the Study of Lung Cancer (IASLC) today ...

Clinical Development Initiated in Greater China by Partner Betta PharmaceuticalsWATERTOWN, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage ...